source
- Moderna awaits FDA decision on mRNA flu vaccine as biotech fund launches and pricing disputes intensifyModerna is awaiting the FDA's decision on its mRNA influenza vaccine, which could become the first seasonal flu shot using messenger RNA technology. Meanwhile, venture firm TCGX announced a new $4…
- AstraZeneca shares drop 5.5% as investors react to reported merger talks with Bristol Myers SquibbAstraZeneca's share price slipped on Monday after Reuters reported that the company is in merger talks with Bristol Myers Squibb. The potential combination would create a drugmaker valued at rough…